NASDAQ:WINT Windtree Therapeutics (WINT) Stock Price, News & Analysis $0.01 0.00 (-10.63%) As of 06/11/2026 03:17 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About Windtree Therapeutics Stock (NASDAQ:WINT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Windtree Therapeutics alerts:Sign Up Key Stats Today's Range$0.0140▼$0.018050-Day Range$0.01▼$0.0352-Week Range$0.01▼$1.86Volume163,898 shsAverage Volume342,657 shsMarket Capitalization$643.33 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Windtree Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative therapies for acute cardiovascular and pulmonary conditions. The company leverages its proprietary KL4 surfactant technology to address diseases marked by surfactant deficiency or dysfunction, with a primary focus on acute respiratory distress syndrome (ARDS) in adults and respiratory distress syndrome (RDS) in premature infants. The company’s lead platform comprises synthetic peptide‐based surfactants designed to restore lung function by reducing surface tension in the alveoli. Windtree’s pipeline includes aerosolized and intratracheal formulations intended for rapid distribution in the lung, including programs that have advanced through preclinical studies and early-stage clinical trials. These programs aim to offer an alternative to animal-derived surfactants and to target patient populations with significant unmet medical needs. Headquartered in Warrington, Pennsylvania, Windtree collaborates with academic research centers and clinical investigators across the United States and Europe to conduct its development programs. The company’s activities encompass formulation optimization, toxicology testing, and multi-site clinical evaluations, supported by partnerships that extend its reach into critical care and neonatal intensive care settings. Under the leadership of President and CEO Michael Ott, Windtree maintains a management team with extensive experience in drug development, regulatory affairs and commercial strategy. The organization is committed to advancing its pipeline through regulatory interactions and clinical milestones in pursuit of therapies that can improve outcomes for patients with serious cardiopulmonary disorders.AI Generated. May Contain Errors. Read More Receive WINT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WINT Stock News HeadlinesWindtree Therapeutics Delays Filing of Annual ReportApril 1, 2026 | tipranks.comCommLoan Achieves Nationwide Regulatory Approval Across All 50 StatesMarch 17, 2026 | prnewswire.comThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the world's largest fund managers - including a section naming one small company Musk's Colossus cannot operate without. Right now, most fund managers have never heard of it. By Friday, every one of them will. Dylan Jovine has identified the name and ticker before $75 billion in new capital starts chasing the SpaceX supply chain. | Behind the Markets (Ad)Windtree Therapeutics Announces Sudden Departure of President and COOJanuary 17, 2026 | theglobeandmail.comWindtree sells heart drug assets, keeps a cut of any future breakthroughDecember 30, 2025 | msn.comWindtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug CandidatesDecember 23, 2025 | finance.yahoo.comWindtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech SpaceDecember 4, 2025 | markets.businessinsider.comWindtree announces it has signed a letter of intent to acquire CommLoanDecember 4, 2025 | msn.comSee More Headlines WINT Stock Analysis - Frequently Asked Questions How have WINT shares performed this year? Windtree Therapeutics' stock was trading at $0.0320 on January 1st, 2026. Since then, WINT stock has decreased by 55.3% and is now trading at $0.0143. How were Windtree Therapeutics' earnings last quarter? Windtree Therapeutics, Inc. (NASDAQ:WINT) released its quarterly earnings results on Tuesday, August, 19th. The company reported ($3.06) EPS for the quarter, beating the consensus estimate of ($99.00) by $95.94. When did Windtree Therapeutics' stock split? Shares of Windtree Therapeutics reverse split on Friday, February 21st 2025.The 1-50 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Windtree Therapeutics? Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Windtree Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Windtree Therapeutics investors own include Plug Power (PLUG), Trevena (TRVN), SNDL (SNDL), AMC Entertainment (AMC), Sphere 3D (ANY), BioCardia (BCDA) and Sonnet BioTherapeutics (SONN). Company Calendar Last Earnings8/19/2025Today6/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WINT CIK946486 Webwww.windtreetx.com Phone(215) 488-9300Fax215-488-9301Employees30Year Founded1992Profitability EPS (Trailing Twelve Months)($8.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-207.34% Return on Assets-50.19% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book0.01Miscellaneous Outstanding Shares44,988,000Free Float3,656,000Market Cap$643.33 thousand OptionableNot Optionable Beta1.62 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:WINT) was last updated on 6/12/2026 by MarketBeat.com Staff. From Our PartnersIs your wealth prepared for “America’s Most Dangerous Man”? (Read before June 16)60-year Wall Street veteran Marc Chaikin is issuing an urgent warning about the billionaire behind an AI lab t...Chaikin Analytics | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredLive demo of Elon Musk’s AI agentJeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...Brownstone Research | SponsoredJon Najarian: “Make this move now that SPCX is trading”SpaceX is now publicly trading under the ticker SPCX - but Hall of Fame Trader Jon Najarian says the real oppo...Banyan Hill Publishing | SponsoredTrump’s Government Went 4 for 4 Last Year … Who’s Next?Last year, the U.S. government bought shares in four companies - and all four surged afterward. MP Materials c...Weiss Ratings | Sponsored45 new billionaires in a single year45 people became billionaires from a single technology last year - in just 12 months. Their combined wealth no...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
